Cough drug safety checked in people with liver issues
NCT ID NCT06222892
Summary
This early-stage study aimed to understand how a potential cough medicine, camlipixant, behaves in people with impaired liver function. It compared 32 adults with varying degrees of liver problems to healthy volunteers. The main goal was to see if the drug's processing and safety profile changed for people with liver disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COUGH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Miami, Florida, 33136, United States
-
GSK Investigational Site
Orlando, Florida, 32809, United States
-
GSK Investigational Site
San Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.